US gives green light to first fast-acting insulin biosimilar for diabetes
The FDA has approved Merilog, a rapid-acting insulin biosimilar to Novolog, marking a new advancement in diabetes treatment. Designed to help manage blood sugar levels effectively, Merilog joins the market as a cost-effective alternative. This approval highlights the FDA’s commitment to expanding treatment options and encouraging pharmaceutical competition. Healthcare providers can now offer patients an additional choice for diabetes management, enhancing flexibility and potentially reducing treatment costs. Merilog’s introduction is a significant step forward in addressing the needs of diabetic patients.